What the Research Revealed Parkinson’s disease (PD) is a growing neurological disorder with no cure, and current treatments focus on managing symptoms. Some researchers believe that newer glucose-lowering drugs (GLDs) used to treat type 2 diabetes might help reduce the risk of PD because both diseases share similar biological pathways, like insulin...
GLP-1 receptor agonists, medications like semaglutide, liraglutide, exenatide, dulaglutide, and lixisenatide, are best known for treating type 2 diabetes and supporting weight loss. But researchers are now exploring something unexpected: could these same drugs also help protect joints in osteoarthritis and strengthen bones in osteoporosis?
A 2025 review in Medicine examined how GLP-1 receptor agonists might affect both conditions. The idea is exciting because osteoarthritis and osteoporosis often occur together in older adults, and currently, no single medication effectively treats both.
GLP-1 receptor agonists are best known as medicines for type 2 diabetes and weight loss. Drugs like semaglutide, liraglutide, and exenatide have become widely used for blood sugar control and obesity. But new research suggests they may also help protect joints and bones. A recent review explores how GLP-1 receptor agonists might reduce inflammation in osteoarthritis...
The U.S. Food and Drug Administration recently announced the issuance of 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites. “It’s a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms—and taking...
Rebalancing the Immune system: new treatments for Autoimmune Disease
Autoimmune diseases happen when the immune system gets confused and starts attacking the body instead of protecting it. Conditions like lupus, rheumatoid arthritis, type 1 diabetes, and multiple sclerosis can be lifelong, painful, and hard to control. For decades, most treatments worked by broadly suppressing the immune system, basically turning the volume down on immunity across the board. But now, researchers are moving toward something much more precise. Instead of shutting down the entire immune response, new immunotherapies aim to retrain or rebalance it. The goal isn’t just symptom control, it’s restoring immune balance while keeping normal defenses intact.
Endometrial cancer is common, but once it spreads or returns after treatment, it becomes very difficult to manage. Clear treatment guidelines are limited, especially for aggressive subtypes like serous endometrial cancer, which grows quickly and often does not respond well to standard therapy. A new case report describes a rare and impressive response to trastuzumab...